Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.70 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.59 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.51 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17693325 | 0.89 | KDM4C (0.73) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17695487 | 0.89 | KDM4C (0.56) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL19272898 | 0.89 | KDM4C (0.57) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17695550 | 0.86 | KDM4C (0.71) | KDM4CKDM2BPHF8KDM5A | |
| SCHEMBL17695549 | 0.85 | KDM4C (0.59) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL16033615 | 0.83 | KDM4C (1.00) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17891763 | 0.81 | PHF8 (0.59) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17693328 | 0.78 | KDM4C (0.58) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL16033837 | 0.78 | KDM4C (0.80) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621542 | 0.77 | KDM4C (0.55) | KDM4CKDM2BPHF8KDM2AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193881-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 14/4885KDM2B 15/4885PHF8 35/4885 |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 14/4885KDM2B 15/4885PHF8 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.